Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial

Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaem...

ver descrição completa

Detalhes bibliográficos
Principais autores: Bousser, M, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, MG, Mattle, H, Rothwell, P, De Cordoüe, A, Fratacci, M
Formato: Journal article
Idioma:English
Publicado em: 2011
_version_ 1826304111459434496
author Bousser, M
Amarenco, P
Chamorro, A
Fisher, M
Ford, I
Fox, K
Hennerici, MG
Mattle, H
Rothwell, P
De Cordoüe, A
Fratacci, M
author_facet Bousser, M
Amarenco, P
Chamorro, A
Fisher, M
Ford, I
Fox, K
Hennerici, MG
Mattle, H
Rothwell, P
De Cordoüe, A
Fratacci, M
author_sort Bousser, M
collection OXFORD
description Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. Methods: This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and investigators were masked to treatment allocation. The primary efficacy endpoint was a composite of fatal or non-fatal ischaemic stroke, fatal or non-fatal myocardial infarction, or other vascular death (excluding haemorrhagic death). We planned a sequential statistical analysis of non-inferiority (margin 1·05) followed by analysis of superiority. Analysis was by intention to treat. The study was stopped prematurely for futility on the basis of the recommendation of the Data Monitoring Committee. This study is registered, number ISRCTN66157730. Findings: 9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); mean follow-up was 28·3 months (SD 7·7). The primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR] 1·02, 95% CI 0·94-1·12). There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. We recorded some increase in minor bleedings with terutroban compared with aspirin (1147 [12%] vs 1045 [11%]; HR 1·11, 95% CI 1·02-1·21), but no significant differences in other safety endpoints. Interpretation: The trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost. Funding: Servier, France. © 2011 Elsevier Ltd.
first_indexed 2024-03-07T06:12:51Z
format Journal article
id oxford-uuid:f01d8dfb-6d2a-44a6-a6e3-5be7551b62a7
institution University of Oxford
language English
last_indexed 2024-03-07T06:12:51Z
publishDate 2011
record_format dspace
spelling oxford-uuid:f01d8dfb-6d2a-44a6-a6e3-5be7551b62a72022-03-27T11:45:21ZTerutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f01d8dfb-6d2a-44a6-a6e3-5be7551b62a7EnglishSymplectic Elements at Oxford2011Bousser, MAmarenco, PChamorro, AFisher, MFord, IFox, KHennerici, MGMattle, HRothwell, PDe Cordoüe, AFratacci, MBackground: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. Methods: This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and investigators were masked to treatment allocation. The primary efficacy endpoint was a composite of fatal or non-fatal ischaemic stroke, fatal or non-fatal myocardial infarction, or other vascular death (excluding haemorrhagic death). We planned a sequential statistical analysis of non-inferiority (margin 1·05) followed by analysis of superiority. Analysis was by intention to treat. The study was stopped prematurely for futility on the basis of the recommendation of the Data Monitoring Committee. This study is registered, number ISRCTN66157730. Findings: 9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); mean follow-up was 28·3 months (SD 7·7). The primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR] 1·02, 95% CI 0·94-1·12). There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. We recorded some increase in minor bleedings with terutroban compared with aspirin (1147 [12%] vs 1045 [11%]; HR 1·11, 95% CI 1·02-1·21), but no significant differences in other safety endpoints. Interpretation: The trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost. Funding: Servier, France. © 2011 Elsevier Ltd.
spellingShingle Bousser, M
Amarenco, P
Chamorro, A
Fisher, M
Ford, I
Fox, K
Hennerici, MG
Mattle, H
Rothwell, P
De Cordoüe, A
Fratacci, M
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title_full Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title_fullStr Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title_full_unstemmed Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title_short Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial
title_sort terutroban versus aspirin in patients with cerebral ischaemic events perform a randomised double blind parallel group trial
work_keys_str_mv AT bousserm terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT amarencop terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT chamorroa terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT fisherm terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT fordi terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT foxk terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT hennericimg terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT mattleh terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT rothwellp terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT decordouea terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial
AT frataccim terutrobanversusaspirininpatientswithcerebralischaemiceventsperformarandomiseddoubleblindparallelgrouptrial